1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Vertex’s VX-548 For Acute Pain May Be Right On Time For Market

Medicare Policy Change In 2025 Favors Non-Opioids

 
• By Mandy Jackson

The company’s NaV1.8 inhibitor succeeded in Phase III acute pain trials and will be submitted for US FDA approval in mid-2024. It may reach the market in time for Medicare reimbursement changes favoring non-opioids.

Abdominoplasty plastic operation to reduce the abdomen and remove cellulite
VX-548 succeeded in Phase III abdominoplasty and bunionectomy studies • Source: Shutterstock

The closely watched Phase III clinical trials for Vertex Pharmaceuticals Incorporated’s NaV1.8 inhibitor VX-548 in the treatment of moderate-to-severe acute pain following abdominoplasty, bunionectomy and other procedures or events successfully met most of the three studies’ endpoints. As a result, the company plans to submit the drug for US Food and Drug Administration approval by mid-2024 and, if approved, it could reach the market in time for Medicare reimbursement changes favoring non-opioids.

Key Takeaways

  • VX-548 achieved statistical significance versus placebo on the primary endpoint in two Phase III studies and was deemed safe and effective in a Phase III single-arm...

Vertex closed up 2.4% at $446.08 – a new all-time high – on 30 January when it reported the Phase III results for VX-548, which showed statistically significant differences versus...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.